This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, T. Articles by Singal, P. K. Search for Related Content PubMed PubMed Citation Articles by Li, T. Articles by Singal, P. K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Antioxidants Hazardous Substances DB DOXORUBICIN Related Collections Congestive Animal models of human disease Heart failure - basic studies Myocardial cardiomyopathy disease Oxidant stress

(Circulation. 2000;102:2105.)
© 2000 American Heart Association, Inc.

Basic Science Reports

Adriamycin-Induced Early Changes in Myocardial Antioxidant Enzymes and Their Modulation by Probucol

Timao Li, PhD; Pawan K. Singal, PhD, DSc

From the Institute of Cardiovascular Sciences, St Boniface General Hospital Research Centre, and Department of Physiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.

Correspondence to Dr Pawan K. Singal, Institute of Cardiovascular Sciences, St Boniface General Hospital Research Centre, Room R3022, 351 Tache Ave, Winnipeg, Manitoba, MB R2H 2A6, Canada. E-mail psingal{at}sbrc.umanitoba.ca

Background—The clinical usefulness of adriamycin is restricted by the development of congestive heart failure. It has been suggested that probucol, a strong antioxidant, completely prevents adriamycin-induced cardiomyopathy without interfering with its antitumor properties. The present study investigated the effects of adriamycin and probucol on myocardial antioxidant enzyme activities and immunoreactive protein levels in rats.

Methods and Results—Activities and protein levels of glutathione peroxidase (GSHPx) were significantly decreased from 2 to 24 hours, and those of manganese superoxide dismutase were decreased at 1 and 2 hours after adriamycin treatment. These changes were prevented by probucol. Catalase activity was increased from 2 to 24 hours after adriamycin treatment, but its protein levels were not significantly changed. Copper zinc superoxide dismutase activity and protein level were not changed at any time. Myocardial lipid peroxidation was found to be significantly higher at all time points, and this change was also prevented by probucol. Treatment with probucol alone increased GSHPx activity at 2 weeks, and in these hearts, lipid peroxidation was lower than the control value. Within 24 hours, there was no mortality in any of the groups.

Conclusions—It is suggested that an early and persistent decrease in GSHPx activity and protein may play an important role in the pathogenesis of adriamycin-induced cardiomyopathy, worsening heart failure and mortality.

Key Words: glutathione peroxidase • lipids • cardiomyopathy • heart failure

This article has been cited by other articles:

				M. Farina, F. Campos, I. Vendrell, J. Berenguer, M. Barzi, S. Pons, and C. Sunol Probucol Increases Glutathione Peroxidase-1 Activity and Displays Long-Lasting Protection against Methylmercury Toxicity in Cerebellar Granule Cells Toxicol. Sci., December 1, 2009; 112(2): 416 - 426. [Abstract] [Full Text] [PDF]

				M. S. Hazari, N. Haykal-Coates, D. W. Winsett, D. L. Costa, and A. K. Farraj Continuous Electrocardiogram Reveals Differences in the Short-Term Cardiotoxic Response of Wistar-Kyoto and Spontaneously Hypertensive Rats to Doxorubicin Toxicol. Sci., July 1, 2009; 110(1): 224 - 234. [Abstract] [Full Text] [PDF]

				N. Mihailovic-Stanojevic, D. Jovovic, Z. Miloradovic, J. Grujic-Milanovic, M. Jerkic, and J. Markovic-Lipkovski Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan Nephrol. Dial. Transplant., April 1, 2009; 24(4): 1142 - 1150. [Abstract] [Full Text] [PDF]

				S. P. Dunn, B. Bleske, M. Dorsch, T. Macaulay, B. Van Tassell, and O. Vardeny Nutrition and Heart Failure: Impact of Drug Therapies and Management Strategies Nutr Clin Pract, February 1, 2009; 24(1): 60 - 75. [Abstract] [Full Text] [PDF]

				G.-C. Fan, X. Zhou, X. Wang, G. Song, J. Qian, P. Nicolaou, G. Chen, X. Ren, and E. G. Kranias Heat Shock Protein 20 Interacting With Phosphorylated Akt Reduces Doxorubicin-Triggered Oxidative Stress and Cardiotoxicity Circ. Res., November 21, 2008; 103(11): 1270 - 1279. [Abstract] [Full Text] [PDF]

				C. Fang, J. Gu, F. Xie, M. Behr, W. Yang, E. D. Abel, and X. Ding Deletion of the NADPH-Cytochrome P450 Reductase Gene in Cardiomyocytes Does Not Protect Mice against Doxorubicin-Mediated Acute Cardiac Toxicity Drug Metab. Dispos., August 1, 2008; 36(8): 1722 - 1728. [Abstract] [Full Text] [PDF]

				L. Li, Q. Pan, W. Han, Z. Liu, L. Li, and X. Hu Schisandrin B Prevents Doxorubicin-Induced Cardiotoxicity via Enhancing Glutathione Redox Cycling Clin. Cancer Res., November 15, 2007; 13(22): 6753 - 6760. [Abstract] [Full Text] [PDF]

				S. Bien, A. Riad, C. A. Ritter, M. Gratz, F. Olshausen, D. Westermann, M. Grube, T. Krieg, S. Ciecholewski, S. B. Felix, et al. The Endothelin Receptor Blocker Bosentan Inhibits Doxorubicin-Induced Cardiomyopathy Cancer Res., November 1, 2007; 67(21): 10428 - 10435. [Abstract] [Full Text] [PDF]

				S. Turakhia, C. D. Venkatakrishnan, K. Dunsmore, H. Wong, P. Kuppusamy, J. L. Zweier, and G. Ilangovan Doxorubicin-induced cardiotoxicity: direct correlation of cardiac fibroblast and H9c2 cell survival and aconitase activity with heat shock protein 27 Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3111 - H3121. [Abstract] [Full Text] [PDF]

				A. J. Chicco, C. M. Schneider, and R. Hayward Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R424 - R431. [Abstract] [Full Text] [PDF]

				X. Peng, B. Chen, C. C. Lim, and D. B. Sawyer The Cardiotoxicology of Anthracycline Chemotherapeutics: TRANSLATING MOLECULAR MECHANISM INTO PREVENTATIVE MEDICINE Mol. Interv., June 1, 2005; 5(3): 163 - 171. [Abstract] [Full Text] [PDF]

				H. Lou, I. Danelisen, and P. K. Singal Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1925 - H1930. [Abstract] [Full Text] [PDF]

				G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]

				M. E. Buyukokuroglu, S. Taysi, M. Buyukavci, and E. Bakan Prevention of acute adriamycin cardiotoxicity by dantrolene in rats Human and Experimental Toxicology, May 1, 2004; 23(5): 251 - 256. [Abstract] [PDF]

				P. Pacher, L. Liaudet, P. Bai, J. G. Mabley, P. M. Kaminski, L. Virag, A. Deb, E. Szabo, Z. Ungvari, M. S. Wolin, et al. Potent Metalloporphyrin Peroxynitrite Decomposition Catalyst Protects Against the Development of Doxorubicin-Induced Cardiac Dysfunction Circulation, February 18, 2003; 107(6): 896 - 904. [Abstract] [Full Text] [PDF]

				J. Nitobe, S. Yamaguchi, M. Okuyama, N. Nozaki, M. Sata, T. Miyamoto, Y. Takeishi, I. Kubota, and H. Tomoike Reactive oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas-mediated apoptosis in cardiac myocytes Cardiovasc Res, January 1, 2003; 57(1): 119 - 128. [Abstract] [Full Text] [PDF]

				Y. T. Sia, N. Lapointe, T. G. Parker, J. N. Tsoporis, C. F. Deschepper, A. Calderone, A. Pourdjabbar, J.F. Jasmin, J.F. Sarrazin, P. Liu, et al. Beneficial Effects of Long-Term Use of the Antioxidant Probucol in Heart Failure in the Rat Circulation, May 28, 2002; 105(21): 2549 - 2555. [Abstract] [Full Text] [PDF]

				S. Itoh, S. Umemoto, M. Hiromoto, Y. Toma, Y. Tomochika, S. Aoyagi, M. Tanaka, T. Fujii, and M. Matsuzaki Importance of NAD(P)H Oxidase-Mediated Oxidative Stress and Contractile Type Smooth Muscle Myosin Heavy Chain SM2 at the Early Stage of Atherosclerosis Circulation, May 14, 2002; 105(19): 2288 - 2295. [Abstract] [Full Text] [PDF]

				P. Pacher, L. Liaudet, P. Bai, L. Virag, J. G. Mabley, G. Hasko, and C. Szabo Activation of Poly(ADP-Ribose) Polymerase Contributes to Development of Doxorubicin-Induced Heart Failure J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 862 - 867. [Abstract] [Full Text] [PDF]

				E. Rabelo, K. De Angelis, P. Bock, T. Gatelli Fernandes, F. Cervo, A. Bello Klein, N. Clausell, and M. Claudia Irigoyen Baroreflex Sensitivity and Oxidative Stress in Adriamycin-Induced Heart Failure Hypertension, September 1, 2001; 38(3): 576 - 580. [Abstract] [Full Text] [PDF]

				K. K. A. Witte, A. L. Clark, and J. G. F. Cleland Chronic heart failure and micronutrients J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1765 - 1774. [Abstract] [Full Text] [PDF]